Table 1.
Demographics and clinical characteristics of the 256 newly diagnosed AML patients in the study set
| Variable category | Number or % |
|---|---|
| No. of cases | 256 |
| % male | 53.8% |
| Race | |
| Asian | 1.9% |
| Black | 8.3% |
| Hispanic | 12.8% |
| White | 76.7% |
| Age, y | |
| Mean | 61.1 |
| Median | 63.8 |
| Minimum | 16.1 |
| Maximum | 87.2 |
| FAB | |
| M0 | 6.5% |
| M1 | 13.8% |
| M2 | 26.8% |
| M4 | 23.4% |
| M4EOS | 3.4% |
| M5 | 2.3% |
| M5A | 5.4% |
| M5b | 3.8% |
| M6 | 2.7% |
| M7 | 1.9% |
| RAEBT | 1.9% |
| Unknown | 8.0% |
| WHO classification | |
| AML with recurrent cytogenetic changes | 29 |
| AML with multilineage dysplasia | 59 |
| AML, therapy related | 36 |
| AML not otherwise categorized | 134 |
| Cytogenetics | |
| Favorable | 8.3% |
| Intermediate | 45.7% |
| Unfavorable | 44.5% |
| ND | 1.5% |
| Zubrod PS | |
| 0-2 | 94.1% |
| 3 or 4 | 5.9% |
| AHD | |
| ≥ 2 mo | 32.1% |
| Response | |
| CR | 56.8% |
| CRP | 3.2% |
| Early death | 0.5% |
| Fail | 8.1% |
| Resistant | 31.1% |
| Inevaluable | 0.5% |
| Relapse | |
| Yes | 54.1% |
| Alive | |
| Yes | 29.4% |
RAEBT indicates refractory anemia with excess of blasts in transformation; AML, acute myeloid leukemia; AHD ≥ 2, antecedent hematologic disorder of greater than or equal to 2 months; CR, complete remission; CRp, complete remission criteria met except that platelets fail to reach 100 000 μL; Early death, death within the first 2 weeks after the start of induction therapy; and Fail, death occurring more than 2 weeks after the start of therapy.